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The altered metabolism of tumor cells confers a se-
lective advantage for survival and proliferation, and
studies have shown that targeting such metabolic
shifts may be a useful therapeutic strategy. We
developed an intensely fluorescent, rapidly respon-
sive, pH-resistant, genetically encoded sensor of
wide dynamic range, denoted SoNar, for tracking
cytosolic NAD+ and NADH redox states in living cells
and in vivo. SoNar responds to subtle perturbations
of various pathways of energy metabolism in real
time, and allowed high-throughput screening for
new agents targeting tumor metabolism. Among >
5,500 unique compounds, we identified KP372-1 as
a potent NQO1-mediated redox cycling agent that
produced extreme oxidative stress, selectively
induced cancer cell apoptosis, and effectively
decreased tumor growth in vivo. This study demon-
strates that genetically encoded sensor-basedmeta-
bolic screening could serve as a valuable approach
for drug discovery.
INTRODUCTION
In recent years, there is renewed attention paid to Otto War-
burg’s observation in 1924 that cancer cells shift energy meta-
bolism from mitochondrial oxidative phosphorylation to aerobic
glycolysis (Warburg, 1956). Cancer cell metabolism is dramati-Ccally reprogrammed to support energy demand and increased
biosynthesis of macromolecules for rapid cell proliferation,
which has attracted many efforts to target it as a selective
anticancer strategy (Cairns et al., 2011; Vander Heiden, 2011;
Vander Heiden et al., 2009). Biochemical methods, including
enzymatic cycling assays, chromatography,mass spectrometry,
and nuclear magnetic resonance spectroscopy, can be used to
assess cellular metabolism and search for new cancer-targeting
agents. Most of these methods require cell lysis, are time inten-
sive, and, therefore, are not suitable for quantitative, real-
time high-throughput screening. High-throughput screening of
such agents in cells or in vivo is muchmore difficult and rarely re-
ported. The use of genetically encoded fluorescent sensors may
be a more suitable approach for metabolic chemical screening.
To date, these sensors have been developed for single-cell
real-time monitoring of several key metabolites (Zhao and
Yang, 2015). Among these metabolites, NAD+ and its reduced
form, NADH, are themost important cofactors involved in energy
metabolism. Recently, Yellen’s group and our group indepen-
dently developed genetically encoded NADH sensors that allow
specific monitoring of dynamic changes in NADH levels in
cytosol or mitochondria as affected by different metabolic states
(Hung et al., 2011; Zhao et al., 2011). These Frex sensors (Zhao
et al., 2011) specifically report NADH levels over a large dynamic
range; however, they do not adapt an optimal tertiary structure in
some cells, and their fluorescence is pH sensitive. Peredox sen-
sors (Hung et al., 2011) are much more pH resistant and partially
reflect the more physiologically relevant NAD+/NADH ratio; how-
ever, they have a limited dynamic range, and their affinity
appears too high to be useful under physiological conditions.
Importantly, neither Frex nor Peredox sensors show obvious
fluorescence response to NAD+. Such limitations make it difficultell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc. 777
Figure 1. Genetically Encoded Sensor for NAD+, NADH, and Their Ratio
(A) Design of SoNar, which is a fusion of cpYFP and the NADH-binding domain of T-Rex. Binding of NAD+ or NADH induces changes in protein conformation and
fluorescence.
(B) Excitation spectra of purified SoNar in the control condition (black), and after addition of 20 mMNAD+ (green) or 20 mMNADH (orange), normalized to the peak
intensity in the control condition. Emission was measured at 530 nm.
(C) Normalized ratio of fluorescence intensities excited at 420 nm and 485 nm (F420 nm/F485 nm) in the presence of different concentrations of NADH and its
analogs.
(D) Fluorescence ratios plotted against the NAD+/NADH ratio at the indicated total nicotinamide adenine dinucleotide concentration. Fluorescence ratios were
normalized to the control condition in the absence of nucleotides.
(E) Fluorescence excited at 420 nm plotted against the NAD+/NADH ratio at the indicated pH. Fluorescence was normalized to the control condition in the
absence of pyridine nucleotides at pH 7.4.
(F) Kinetics of fluorescence response of purified SoNar, Peredox, and cpYFP protein to sequential addition of 0.2 mMNADH and 2 mMNAD+. In (C)–(F) error bars
represent SEM. See also Figure S1 and Table S1.to use these sensors for measuring metabolic states in vivo and
in high-throughput screening.
Herein, we report the development of an intensely fluorescent,
rapidly responsive, pH-resistant, genetically encoded sensor of
wide dynamic range, denoted SoNar, for the detection of cyto-
solic NAD+ and NADH redox states in living cells and in vivo.
This sensor of superior properties allowed high-throughput
metabolic screening of > 5,500 unique compounds in cancer
cell lines. We found that many compounds that increased the
NAD+/NADH ratio exhibited marked cancer cell cytotoxicity.
Among them, KP372-1, the most potent in increasing NAD+/
NADH ratio and cancer cell killing, also effectively decreases tu-
mor growth in vivo. Further studies revealed that KP372-1 is an
NQO1-catalyzed, NAD(P)H-consuming redox cycling agent
that produces extreme oxidative stress in cancer cells.
RESULTS
Generation of a Genetically Encoded Fluorescent
Sensor for Detection of NAD+, NADH, and Their Ratio
A total of 15 chimeric proteins were designed, in which cpYFP
was inserted between two complete or truncated subunits of778 Cell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc.Rex protein from Thermus aquaticus (T-Rex), or between amino
acid residues located on surface loops of T-Rex (Figure S1A).
Among them, the chimera with cpYFP inserted after Phe189 of
T-Rex showed a 300% increase in the ratio of fluorescence
when excited at 420 nm and 485 nm upon NADH addition (Fig-
ure S1B). We then created a series of truncated variants of this
protein, either with or without the DNA-binding domain of T-
Rex, targeting residues involved in the linker between Rex and
cpYFP (Figures S1C and S1D), and found the D2-C2N0 variant
to manifest the most dramatic increase in the fluorescence ratio
when excited at 420 and 485 nm in the presence of NADH (Fig-
ures 1A, 1B, and S1D–S1G). Intriguingly, in the presence of
saturating NAD+, D2-C2N0 exhibitedmarked increase in fluores-
cence when excited at 485 nm (Figures 1B and S1G).
Fluorescence titration studies showed that D2-C2N0 had an
apparent dissociation constant (Kd) 5.0 mM and 0.2 mM,
respectively, for NAD+ and NADH at pH 7.4 (Figure 1C), far
below the total intracellular pool of NAD+ and NADH in the
range of hundreds micromolar (Yamada et al., 2006; Yang
et al., 2007). Intracellularly, the sensor would be occupied
by either NAD+ or NADH molecules, and its steady-state
fluorescence would report the NAD+/NADH ratio rather than
the absolute concentrations of the two nucleotides (Figure 1D).
We find that D2-C2N0 has an apparent KNAD
+
/NADH of 40, the
ratio of NAD+ and NADH at which the response is half-maximal,
and is analogous to the Kd of a ‘‘receptor’’ for the redox couple.
The sensor has high selectivity toward the NAD+/NADH ratio,
showing no apparent fluorescence changes toward or in the
presence of analogs like NADP+, NADPH, ATP, or ADP (Figures
1C and S1H–S1J). The opposing directional changes of D2-
C2N0 fluorescence in the presence of NAD+ and NADH
rendered a 15-fold dynamic range, making the sensor among
the most responsive genetically encoded sensors available to
date (Figure 1D). D2-C2N0 fluorescence excited at 420 nm
was much less sensitive to pH, allowing the measurement of
NADH levels when modest pH fluctuations occur (Figure 1E).
By contrast, D2-C2N0 fluorescence when excited at 485 nm
was sensitive to pH, but its dynamic range and KR are more
pH resistant (Figures S1K and S1L). Thus, the pH effects can
be alternatively corrected by measuring D2-C2N0’s and
cpYFP’s fluorescence in parallel, owing to their very similar
pH responses (Figures S1L and S1M). Furthermore, kinetic
studies showed that the fluorescence of D2-C2N0 responded
immediately to sequential addition of NADH and NAD+ (Fig-
ure 1F), suggesting its usefulness in real-time measurements.
Collectively, these data show that D2-C2N0 is highly sensitive
and selective for NAD+ and NADH, has rapid responses and
a large dynamic range, and is an effective ratiometric sensor
for NAD+, NADH, and their ratio with its uniquely designed
structure. We therefore termed it SoNar (sensor of NAD(H)
redox), and used it for all subsequent experiments.
Select Tumor Cell Lines Exhibit Decreased NAD+/NADH
Redox State
In H1299 human lung cancer cells, SoNar demonstrated much
more intense fluorescence compared to the Frex sensor and to
a palette of other genetically encoded sensors (Figure S2A),
owing to its robust folding and short coding sequence. In
cytosol, pyruvate and lactate are generally believed to be in equi-
librium with free NAD+ and NADH through the catalytic action of
lactate dehydrogenase (LDH). In cells stably expressing SoNar,
exogenous pyruvate induced an instantaneous, up to 3-fold
decrease in the ratio of fluorescence with excitation at 420 and
485 nm, which then recovered slowly (Figures 2A, 2B, and
S2B). Such effects of pyruvate were almost completely inhibited
by the monocarboxylate transporter inhibitor AR-C155858 or
LDH inhibitor oxamate (Figure 2D). In control experiments,
fluorescence changes were significantly smaller for Frex and
Peredox sensors, and occurred much more slowly for the Pere-
dox sensor (Figures S2B and S2C). The more rapid responses of
SoNar were due to the faster dissociation rate of the SoNar-
NADH complex (Figure 1F). The LDH inhibitor oxamate
increased the ratio of SoNar’s fluorescence more effectively
than lactate (Figures 2C, S2D, and S2E). When cells were treated
with pyruvate and oxamate simultaneously, the ratio of SoNar’s
fluorescence rapidly decreased initially, and then gradually
increased similarly to that caused by oxamate alone (Figure 2C).
These data suggest that pyruvate immediately increases the
cellular NAD+/NADH ratio, while inhibition of LDH blocked
NAD+ recycling and gradually decreased the cellular NAD+/
NADH ratio, consistent with previous reports (Le et al., 2010).CWe then quantified the cytosolic NAD+/NADH ratio utilizing
SoNar’s fluorescence (Figures 2E, S2F, and S2G). The results
showed heterogeneity among both cancer cells and non-cancer
cells. H1299 and several other cancer cell lines showed signifi-
cantly lower NAD+/NADH ratios. In these cells, the LDH inhibitor
was more potent than mitochondrial NADH oxidase inhibition
in reducing the NAD+/NADH ratio, whereas in non-cancer cells,
amalate-aspartate shuttle inhibitorwas lesspotent than themito-
chondrial NADH oxidase inhibitor in decreasing the NAD+/NADH
ratio (Figure 2F). These results suggest thatH1299cells are highly
dependent on glycolysis; mitochondrial respiration is sufficiently
functional to oxidize NADH derived from glycolysis, but not
NADH derived from the TCA cycle. Further studies showed that
inhibition of glycolysis with 3-bromopyruvate (3-BrPA) markedly
increased, whereas glucose supplementation decreased, the
intracellular NAD+/NADH ratio (Figures S2H–S2J). The glucose
concentration for the half-maximal SoNar fluorescence response
is 0.26 mM in H1299 cells and 1.4 mM in HEK293 cells (Fig-
ure S2J), again suggesting that these cancer cells had higher
glycolytic activity utilizing lower concentrations of glucose and
thereby maintaining their cytosolic NAD+/NADH ratio.
The intense fluorescence of the SoNar sensor allows imaging
of cellular redox states in vivo. To this end, nude mice were
subcutaneously (s.c.) inoculated with H1299 cells stably ex-
pressing SoNar or cpYFP, and imaged when the tumor reached
0.6–1.2 cm. When the mice received an intravenous injection of
110 mg/kg sodium pyruvate, with excitation at 420 and 490 nm,
the ratio of SoNar fluorescence in the tumor decreased immedi-
ately and then gradually recovered over 25 min (Figures 2G and
2I), suggesting that pyruvate in the blood stream significantly
affected the NAD(H) redox state in the tumor tissue. In contrast,
tumor tissue expressing cpYFP instead of SoNar showed no
obvious fluorescence changes upon pyruvate injection, thereby
excluding the possibility of interference of the sensor’s fluores-
cence due to pH variations (Figures 2H and 2I). Taken together,
these data indicate that the SoNar sensor displays a superior
response, fluorescence intensity, and large dynamic range,
and is very useful for the real-time tracking of subtle differences
in cellular metabolic and redox states in vitro and in vivo.
SoNar-Based High-Throughput Screening for
Compounds Affecting Cancer Cell Metabolism
To identify drugs that selectively target cancer cell metabolism,
we screened 23 libraries of > 5,500 unique compounds from
commercial libraries according to their effects on the intracellular
NAD+/NADH redox state of H1299 cells reported by the SoNar
sensor (Figures 3A, 3B, and S3A; Table S2). An index was estab-
lished to describe the intracellular metabolic variation induced by
different compounds. While the majority of these compounds
have close to zero index and, therefore, minimal impact on
SoNar fluorescence and the cellular NAD+/NADH redox state,
we did identify 78 compounds that significantly decreased
the NAD+/NADH ratio in H1299 cells (index > 0.2, 1.4% of
total library) and 12 compounds that significantly increased
the NAD+/NADH ratio in H1299 cells (Figures 3B, 3C, and S3B;
Table S2). The majority of the compounds that increased (8 of
12) the NAD+/NADH ratio exhibited obvious H1299 cell toxicity
(Figures 3C–3E, S3D, and S3E), while only a small fraction of
the compounds that decreased (9 of 78) the NAD+/NADH ratioell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc. 779
Figure 2. Imaging and Quantifying the NAD+/NADH Ratio in Living Cells and In Vivo
(A) Fluorescence images of SoNar or cpYFP-expressing cells before and immediately after incubation with 1 mM pyruvate. Images were pseudocolored with the
ratio of fluorescence excited at 425 nm and 482 nm. Scale bar, 10 mm.
(B) Kinetics of SoNar fluorescence responses in H1299 cells treated with exogenous pyruvate.
(C) Kinetics of SoNar fluorescence responses in H1299 cells treated with pyruvate, oxamate, or pyruvate and oxamate. Data were obtained with a fluorescence
plate reader.
(D) SoNar fluorescence responses in H1299 cells treated with pyruvate were blocked by AR-C155858 or oxamate. Data were normalized to samples without
pyruvate addition.
(E) NAD+/NADH ratio in different primary cell cultures and cell lines quantified according to SoNar fluorescence.
(F) Effect of oxamate, rotenone, and AOA on fluorescence ratios of different cells expressing SoNar. Cells were treated with inhibitors for 10 min. Green,
DFOxamate/DFRotenone; orange, DFRotenone/DFAOA.
(G andH) In vivo fluorescence imaging of H1299 xenografts expressing SoNar or cpYFP in response to intravenously administered pyruvate. Sequential frames of
fluorescence images of SoNar (G) or cpYFP (H) pseudocolored to the fluorescence ratio. Scale bar, 2 mm.
(I) Quantification of the NAD+/NADH ratio in H1299 xenografts according to the SoNar fluorescence data in (G) and (H); error bars represent SD. All experiments
performed in H1299 cells, and error bars represent SEM unless otherwise indicated. See also Figure S2.exhibited obvious cell toxicity (Figures S3B and S3C). It is inter-
esting that three of eight of these compounds—b-lapachone,
shikonin, and fascaplysin—were potent, widely studied anti-
tumor agents. b-lapachone was known to affect cell metabolism
by redox cycling and consuming NAD(P)H (Pink et al., 2000),
while shikonin was reported to inhibit pyruvate kinase M2
(Chen et al., 2011); however, as far as we are aware, the other
compounds have never been directly linked to energy meta-
bolism. Of particular note is the Akt inhibitor, also known as
KP372-1 (Figure 3F). This compound is not only the most potent
agent in increasing the NAD+/NADH ratio, but also the most780 Cell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc.potent cancer cell cytotoxic compound, which decreased the
viability of a wide range of cancer cells of different origin at con-
centrations as low as 100 nM. Importantly, and by contrast, the
compound showed low toxicity toward various primary cells
(Figures 3B, 3C, and 3G).
KP372-1 Affects Tumor Metabolism and Suppresses
Tumor Growth In Vivo
We then proceeded to study the effect of KP372-1 on tumor
metabolism in vivo. Pharmacokinetic studies after a single intra-
venous or intragastric dose (Figure S4A) demonstrated that
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Figure 3. SoNar-Based High-Throughput Screen for Compounds Affecting Cancer Cell Metabolism
(A) Schematic of the drug screen. H1299 cells expressing SoNar were incubated with compounds in 384-well plates for 4 min and fluorescence measured.
(B) Effects of 5,501 compounds on the index ratio, (ZCompoundZControl)/(ZOxamateZPyruvate). The mean value and SD of the experimental population screened is
expressed as ZScores. Orange, low concentration; green, high concentration.
(C) The 12 lowest indexed hits that increase intracellular NAD+/NADH ratio and their effects on cell viability.
(D and E) Fluorescence images of H1299 cells expressing SoNar (D) or cpYFP (E) before and 4 min after treatment with different hit compounds (10 mM). Images
were pseudocolored with the ratio of fluorescence excited at 425 nm and 482 nm. Scale bar, 10 mm.
(F) Chemical structure of KP372-1.
(G) Effects of different concentrations of KP372-1 on the viability of 5 primary cell cultures and 21 cancer cells. All experiments were performed in H1299 cells
unless otherwise indicated. See also Figure S3 and Table S2.KP372-1 has good bioavailability with relatively low clearance,
a long half-life, and good volume of distribution (Table S3). In
tumor-bearing mice in which H1299 cells stably expressing
SoNar were s.c. implanted, administration of KP372-1 by tail
vein injection significantly decreased the ratio of SoNar fluores-
cence with excitation at 420 and 490 nm in the tumor (Figures
4A and S4B), an effect that did not recover during the 1-hr time
course of observation. As a control, minimal changes of fluores-
cence were observed in cpYFP-expressing tumor tissues with
KP372-1 treatment (Figures 4B and S4B). These results suggest
that KP372-1 readily enters tumor tissue and induces persistent
oxidation of NADH in cancer cells (Figure 4C).
We next observed that KP372-1 profoundly suppressed the
growth of the H1299 xenografts implanted s.c. into nude miceCversus vehicle (Figures 4D, 4E, and S4C). Staining sections of
harvested xenografts revealed that KP372-1 reduced prolifera-
tion (Ki67 staining), increased caspase-3 activity, and induced
apoptosis (TUNEL staining) (Figure S4D), consistent with in vitro
studies showing that KP372-1 increases apoptosis and cas-
pase-3 activation in H1299 cells (Figures S4E–S4G). KP372-1-
treated H1299 cells showed significant mitochondrial membrane
permeabilization and enhanced Bax localization inmitochondria,
suggesting apoptosis occurred through amitochondrial pathway
(Figures S4H and S4I). These characteristics of mitochondrial
apoptosis also occurred in KP372-1-treated A549 cells, another
non-small-cell lung cancer (NSCLC) cell line (Figures S4J–S4M).
No toxic effects or other indicators of illness, including signif-
icant weight loss (Figure S4N) or tissue damage (macroscopic orell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc. 781
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Figure 4. KP372-1 Induces NADH Oxidation and Impairs Tumor Growth In Vivo without Apparent Toxicity
(A and B) In vivo ratiometric fluorescence imaging of H1299 xenografts expressing SoNar (A) or cpYFP (B) in response to KP372-1. Images were pseudocolored
with the ratio of fluorescence excited at 420 nm and 490 nm. Scale bar, 2 mm.
(C) Quantification of the NAD+/NADH ratio in H1299 xenografts according to SoNar fluorescence. Error bars represent SD.
(D) H1299 tumor-growth curves of untreated or KP372-1-treated mice. Error bars denote SEM (n = 8 in each group).
(E) Photographs of tumors after dissection at day 33.
(F) H&E staining for the indicated tissues in animals treated with vehicle, 10 mg/kg KP372-1, or 20 mg/kg KP372-1 daily for 33 days. See also Figure S4 and
Table S3.microscopic), were observed in these mice. Pathological review
of sections and an apoptosis assay of heart, liver, lung, and kid-
ney also showed no signs of cytotoxicity (Figures 4F and S4P).
The results of blood, liver, and kidney function tests were also
normal (Figure S4O). These studies suggest the safety of
KP372-1 for use as anticancer therapy.
KP372-1 Induces Significant Oxidative Stress and
Activates the Pentose Phosphate Pathway
We performed metabolomic analysis to gain insight into how
KP372-1 affected cancer cell metabolism, and identified 269
metabolites of known identity (Figures 5A and S5A; Table S4).
Most prominently, many intermediates in the pentose phos-
phate pathway (PPP) increased 7- to 8-fold at 5 min and sus-
tained these elevations at 60 min in response to KP372-1
(Figure 5A; Table S4). There were minimal changes in the levels
of glycolytic metabolites, including lactate, in response to
KP372-1, with the exception of a precipitous decrease of fruc-
tose-1,6-diphosphate (Figure 5A; Table S4). Biochemical anal-
ysis of cell culture medium and cell lysate indicated that both
intracellular and extracellular lactate production remained
constant (Figures S5C and S5F), again suggesting that direct
perturbation of glycolysis was not significant. Biochemical anal-
ysis showed that both intracellular and extracellular pyruvate
increased significantly in response to KP372-1 treatment (Fig-
ures S5B and S5E), consistent with the increased cytosolic
NAD+/NADH ratio (Figure S5D). For metabolites involved in the
TCA cycle, a-ketoglutarate and succinate increased at 5 min
and further increased by 60 min (Figure 5A), suggesting cumula-782 Cell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc.tive effects over time. Metabolomic studies validated the
decrease of NADH level and increase of NAD+ level. KP372-1
also markedly lowered glutathione (GSH) levels and elevated
NADP+ and oxidized GSH (GSSG) levels (Figures 5B and
S5G). Although NADPH was not identified in the metabolomic
analysis, conventional biochemical assay showed that cellular
NADPH levels decreased 4.5-fold, whereas NADP+ levels
increased 4.5-fold after 5 min of KP372-1 treatment (Figures
5C and 5D).
The dose-dependent effects of KP372-1 on intracellular
NADH, H2O2, and disulfide redox state were further explored
by genetically encoded sensors, including SoNar, Hyper (Belou-
sov et al., 2006), and roGFP1 (Dooley et al., 2004). KP372-1
induced significant oxidative stress via oxidizing NADH, gener-
ating H2O2, and oxidizing thiols to disulfides, respectively, two
to three orders of magnitude more efficiently than H2O2 or thiol
oxidants, such as aldrithiol-2 and diamide (Figures 5E–5G,
S5H–S5J, S5L, and S5M). In controls, none of these compounds
affected the fluorescence of cpYFP-expressing cells (Fig-
ure S5K). Kinetic studies showed that the decrease of NADH
occurred immediately after KP372-1 addition, followed by
H2O2 production and then thiol oxidation (Figure S5N). Overall,
these results suggest that KP372-1 has a prominent impact on
cellular redox state with NAD(P)H oxidation being the vanguard
event. Oxidative stress is necessary for KP372-1-induced cell
death, which was largely blocked by overexpressing catalase
in the cell, or by treating the cell with N-acetylcysteine, a general
antioxidant, or Tiron, a cell-permeable superoxide scavenger
(Figures S5O and S5P).
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Figure 5. KP372-1 Induces Significant Oxidative Stress and Activates the Pentose Phosphate Pathway
(A) Metabolite profiles of KP372-1-treated cells shown as a heatmap. Increased metabolite concentrations are shown in red, whereas decreased metabolite
concentrations are shown in green. H1299 cells were treated with 5 mM KP372-1 for 5 min and 60 min, respectively.
(B) KP372-1-induced oxidation of intracellular NADH and GSH. Data obtained by metabolomic studies as in (A) (n = 5 in each group). ***p < 0.001. NS, not
significant.
(C and D) Intracellular NADP+ (C) and NADPH (D) levels with or without 5 mM KP372-1 in H1299 cells. Data obtained by a single extraction method and in vitro
biochemical assay (n = 5 in each group). ***p < 0.001. NS, not significant.
(E–G) Fluorescence responses of cells expressing SoNar (E), Hyper (F), and roGFP1 (G) to different concentrations of KP372-1 and other oxidants. Fluorescence
was measured immediately after chemical addition and normalized to the control condition. All experiments were performed in H1299 cells; error bars represent
SEM. See also Figure S5 and Table S4.NQO1 Catalyzes NAD(P)H-Dependent KP372-1 Redox
Cycling and Promotes Cancer Cell Death
We considered that KP372-1 may activate NAD(P)H-dependent
reactive oxygen species (ROS)-generating enzymes in view of its
potency in inducing oxidative stress, and explored the functions
of such oxidases by overexpressing them in H1299 cells (Figures
6A, S6A, and S6F). We found that only overexpression of NQO1
boosted KP372-1’s effects on intracellular NADH oxidation,
H2O2 production, thiol oxidation, and cell death (Figures 6A,
S6A, and S6C). NQO1 is a promising therapeutic target in cancer
therapy and highly expressed in many cancer cell lines (Bey
et al., 2007; Cullen et al., 2003; Pink et al., 2000), including the
A549 NSCLC cell line (Bey et al., 2007) (Figure S6H). In A549
cells, KP372-1-induced oxidative stress and cell death were
largely inhibited by dicoumarol, a known inhibitor of NQO1
(Pink et al., 2000) (Figures 6B, S6B, and S6D). In contrast, phar-Cmacologic inhibitors of NAD(P)H oxidase, ENOX1, ENOX2,
NQO2, mitochondrial respiratory chain complex I, xanthine oxi-
dase, and nitric oxide synthase showed minimal effects on
KP372-1-induced oxidative stress and cell death (Figures 6B
and S6B). Consistent with the SoNar measurement, data calcu-
lated from the measured concentrations of the pyruvate and
lactate, and the equilibrium constants of LDH (Williamson
et al., 1967), also showed that cytosolic NAD+/NADH ratio was
dose-dependently increased in the cells treated with KP372-1,
which is promoted by NQO1 expression (Figure S6E) or
repressed by the NQO1 inhibitor dicoumarol (Figure S6G). We
next generated isogenic, NQO1 knockout A549 cell lines using
the CRISPR-Cas9 system (Cong et al., 2013; Ran et al., 2013).
These NQO1 knockout lines, confirmed by sequencing and
western blotting, were much more resistant to oxidative stress
and cell death induced by KP372-1 (Figures 6C–6G and S6I).ell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc. 783
(legend on next page)
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Similarly, these NQO1 knockout lines were also much more
resistant to oxidative stress and cell death induced by b-lapa-
chone (Figure S6J), another hit compound in our screen (Figures
3B and 3C) and an anti-tumor agent known to target to NQO1
(Bey et al., 2007; Pink et al., 2000). Interestingly, the only two
cancer cell lines resistant to KP372-1 toxicity in this study,
MDA-MB-231 cells and H596 cells, were also NQO1 negative
(Figures 6H and 6I), while the killing effects of KP372-1 on other
cancer cell lines expressing NQO1 were effectively attenuated
by dicoumarol (Figures 6H and 6I). b-lapachone showed a similar
cytotoxicity profile as KP372-1 and was similarly antagonized by
dicoumarol (Figure S6K).
It is known that a subset of NSCLC cell lines and tumors exhibit
KEAP1 mutations which activate NRF2 (Dai et al., 2013; Singh
et al., 2006). In these cells NRF2 then induces expression of
NQO1, as well as a palette of antioxidant genes (Gorrini et al.,
2013; Sporn and Liby, 2012; Thimmulappa et al., 2002). In
KEAP wild-type cells, there is a good correlation between the
cytotoxicity of KP372-1 and NQO1 expression (Figures S6L
and S6M). In KEAP1 mutant cells, however, there is no clear cor-
relation between the cytotoxicity of KP372-1 and the KEAP
mutation (Figures S6L and S6M), suggesting the effects of over-
expressed NQO1 may be counterbalanced by the enhanced
antioxidant mechanism (Figures S6N and S6O).
The role of NQO1 in KP372-1 toxicity is further supported by
in vivo data, which showed that the growth of the A549 xeno-
grafts was significantly suppressed by KP372-1 compared with
vehicle (Figures 6J and 6K). In contrast, the growth of NQO1
knockout A549 xenografts was not suppressed by KP372-1
compared with vehicle (Figures 6L and 6M). Similarly, growth
of NQO1 knockout H1299 xenografts wasmuch less suppressed
by KP372-1 (Figures 6N, 6O, and S6P) compared to wild-type
H1299 xenografts (Figures 4D, 4E, and S4C).
KP372-1 is known to inhibit Akt kinase (Koul et al., 2006; Man-
dal et al., 2005, 2006; Zeng et al., 2006). Interestingly, our data
showed that the effects of KP372-1 on the fluorescence of
SoNar or roGFP1 were absent when A549 and H1299 cellsFigure 6. NQO1 Catalyzes NAD(P)H-Dependent KP372-1 Redox Cyclin
(A) Overexpression of NQO1, but not other NAD(P)H oxidases, increases KP372-
H1299 cells.
(B) The NQO1 inhibitor dicoumarol, but not other pharmacologic inhibitors of R
production, thiol oxidation, and cell death in A549 cells. For (A) and (B), after cells
while Hyper and roGFP1 fluorescence were measured after 10 min.
(C–F) Knockout of NQO1 decreased KP372-1-induced cell death (C), NADH oxida
fluorescence (E), and thiol oxidation measured by roGFP1 fluorescence (F) in A5
(G) The effect of NQO1 inhibitor dicoumarol or NQO1 knockout on KP372-1-in
concentrations of KP372-1 for 10 min.
(H) Phosphorylation of Akt in different cells treated with 0.5 mM KP372-1 at the in
(I) The effect of NQO1 inhibitor dicoumarol on KP372-1-induced cell death. Cells w
and then grown for 24 hr.
(J–O) The effects of KP372-1 on tumor growth of WT A549 (J and K), NQO1 knock
growth curves (J, L, and N) were measured in untreated or KP372-1-treated mice;
38 (K and M) or day 28 (O), photographed (left), and weighted (right). Error bars i
(P) NQO1-catalyzed NADH oxidation in the presence of different concentrations
centrations of KP372-1 are indicated adjacent to each curve.
(Q) Oxygen consumption of NADH solution (600 mM) in the presence or absence
measured with a BD Oxygen Biosensor System.
(R) Superoxide production by a lucigenin chemiluminescence assay in an assay s
1 mg/ml NQO1 and/or 30 U/ml superoxide dismutase.
(S) Hypothetical model for KP372-1-mediated redox cycling. Error bars represen
Cwere treated with different Akt inhibitors (Figures S6Q–S6T).
Surprisingly and in contradistinction to previous reports that
KP372-1 inhibited Akt phosphorylation in cancer cells (Koul
et al., 2006; Mandal et al., 2005, 2006; Zeng et al., 2006), we
found that KP372-1 treatment dramatically, transiently, and
dose-dependently increased phosphorylation of Akt in A549
and H1299 cells (Figures 6G and S6U), which was not signifi-
cantly affected by NQO1 inhibition or NQO1 knockout (Fig-
ure 6G). Such enhanced Akt phosphorylation induced by
KP372-1 also occurred to varying extents in other cancer cell
lines irrespective of their NQO1 expression level (Figure 6H).
These data showed that KP372-1’s action on NAD+/NADH
redox, oxidative stress, and viability of cancer cells was not
due to the inhibition of this kinase.
NQO1 is a NAD(P)H-dependent oxidoreductase that cata-
lyzes the 2-electron reduction of a broad range of quinones.
b-lapachone was previously reported to exert its anti-tumor
function by ‘‘bioactivation’’ by NQO1 to an unstable hydroqui-
none that rapidly undergoes a two-step oxidation back to the
parent compound, perpetuating a futile redox cycle and gener-
ating superoxide in the process (Pink et al., 2000; Reinicke
et al., 2005). We found that NAD(P)H was rapidly oxidized in
the presence of both KP372-1 and trace amounts of NQO1
in vitro, monitored by either NAD(P)H endogenous fluorescence
(Figures 6P and S6V) or SoNar (Figure S6W). The oxidation of
NADH was accompanied by oxygen consumption (Figure 6Q)
and generation of superoxide and hydrogen peroxide (Figures
6R and S6X). In these studies, greater than 1,000 molar
equivalents of NADH were oxidized per molar equivalent of
KP372-1 in 30 min (Figure 6P), suggesting that KP372-1 under-
went NQO1-dependent redox cycling. In H1299 cells, oxygen
consumption also significantly increased in the presence
of KP372-1, which further increased with overexpression of
NQO1 (Figure S6Y). Taken together, our findings provide evi-
dence that NQO1-mediated futile redox cycling of KP372-1
(Figure 6S) induced oxidative stress and cell death in cancer
cells.g and Promotes Cancer Cell Death
1-induced NADH oxidation, H2O2 production, thiol oxidation, and cell death in
OS-generating enzymes, decreases KP372-1-induced NADH oxidation, H2O2
were treated with KP372-1, SoNar fluorescence was measured immediately,
tionmeasured by SoNar fluorescence (D), H2O2 productionmeasured by Hyper
49 cells.
duced phosphorylation of Akt in A549 cells. Cells were treated with different
dicated times.
ere exposed to a 4-hr pulse of KP372-1 either with or without 50 mMdicoumarol
out A549 (L and M), and NQO1 knockout H1299 (N and O) xenografts. Tumor-
error bars denote SEM (n = 8 in each group). Xenografts were dissected at day
ndicate SEM.
of KP372-1. NADH was measured by its endogenous fluorescence. The con-
of 1 mg/ml NQO1 and different concentrations of KP372-1. Oxygen levels were
olution containing 600 mM NADH and KP372-1, in the presence or absence of
t SEM. See also Figure S6.
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DISCUSSION
The SoNar sensor described herein represents a substantial
improvement for live cell NAD+/NADH measurement over exist-
ing reporters. First, SoNar fluorescence is intrinsically ratiometric
with two excitation wavelengths having opposing responses to
NAD+ and NADH, allowing quantitative determination of NAD+
or NADH separately as well as ratiometrically. To our knowledge,
such a dual-response property is unprecedented among genet-
ically encoded sensors developed to date. In addition to its role
in energy metabolism, NAD+ also participates in a wide range of
cellular processes, acting as precursor of signaling molecules
such as cADPR and ADPR, and as a co-substrate of regulatory
enzymes of significant importance, such as mono- or poly-
ADP-ribose polymerases and Sirt family deacylases. Many of
these enzymes are also important targets for drug discovery.
SoNar is capable of reporting NAD+ levels directly in vitro inde-
pendent of NADH, and can be utilized in simple, continuous
enzymatic assays, which may be amenable to high-throughput
screening. Second, SoNar is an authentic reporter of the
NAD+/NADH ratio under physiological conditions. SoNar had
an apparent Kd of 5.0 mM for NAD+, much lower than intracel-
lular NAD+ concentration, allowing the sensor to report the
NAD+/NADH ratio under physiological conditions accurately un-
affected by the total NAD(H) pool. By contrast, the Frex sensor
reports only NADH levels, while Peredox reports the cytosolic
NADH level, partly compensated by the NAD+ level, rather than
the precise NAD+/NADH ratio (Hung et al., 2011). Third, SoNar
displays a superior rapid response and large dynamic range,
and is very useful for the real-time tracking of subtle differences
in cellular metabolic states. SoNar displays a 1,500% fluores-
cence change under different NAD+/NADH ratios in vitro, almost
10-fold greater than that of Peredox and 2-fold greater than that
of Frex, making it one of the most responsive genetic-encoded
sensors currently available. SoNar responded well to conven-
tional metabolic perturbations such as extraneous glucose, py-
ruvate, and lactate supplementation, or inhibition of energy
metabolism pathways such as mitochondrial respiration, the
mitochondrial NADH shuttle, glycolysis, and LDH. In live cell
studies, the sensor displayed an 8-fold dynamic range, and
was able to detect the response to added pyruvate as low as
5 mM, substantially outperforming either Frex or Peredox sen-
sors. SoNar also performed nicely in in vivo imaging studies, ex-
hibiting intense fluorescence and the ability to detect increases
or decreases in NAD+/NADH levels within normal physiological
conditions. Our study showed that Peredox was not able to
detect the decrease in the NAD+/NADH ratio when cells were
treated with lactate or an LDH inhibitor, as it was almost fully
saturated by NADH in cells in the presence of 1 mM glucose
(Hung et al., 2011). This deficiency complicates Peredox’s usage
for in vivo imaging, considering the normal range of blood
glucose concentration.
Various studies suggested that the intracellular NAD+/NADH
pool is greatly reduced in many cancer cells compared to non-
cancer cells, inferred by the lower lifetime of NADH endogenous
fluorescence and increased mitochondrial free NADH, or lower
ratio of the fluorescence intensity of FAD-to-NADH (Ostrander
et al., 2010; Pradhan et al., 1995; Skala et al., 2007; Yu and
Heikal, 2009); however, to our knowledge, the intracellular786 Cell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc.NAD+/NADH ratio had not been rigorously quantified due to
lack of appropriate quantitative non-invasive methodology. By
monitoring SoNar’s fluorescence, we provide direct evidence
that the cytosolic NAD+/NADH ratio is significantly reduced in
certain cancer cell lines, such as H1299, U87, and MDA-MB-
468. Further dissection of the metabolic pathways governing
this ratio using enzyme inhibitors showed that these cancer cells
were able to utilize low levels of glucose and exhibit high glyco-
lytic activity, consistent with a previous report that H1299 cells
overexpress pyruvate kinaseM2 and display high rates of glycol-
ysis (Christofk et al., 2008). For reference, we attach a diagram
that explains the central role NAD+/NADH plays in relevant
metabolic pathways in this study (Figure S2K).
The intense fluorescence and large dynamic range of SoNar
enabled its usage in robust high-throughput and real-time
screening assays of small-molecule libraries that may affect
cellular metabolism, which may be useful as probes for meta-
bolic studies and as lead compounds for drug discovery. In
contrast tomany other high-throughput assays in drug discovery
that target a single protein or enzyme, SoNar is multi-targeted as
it is capable of reporting subtle perturbations in many pathways
affecting energy metabolism, including glycolysis and mito-
chondrial respiration. Furthermore, the rapid response and
high sensitivity greatly reduce the costs of and time needed for
screening. Most of the compounds that we screened did not
affect intracellular NAD+ redox states; however, protein kinase
inhibitor and phosphokinase inhibitor libraries had a significant
percentage of hits, highlighting the regulatory roles of protein
phosphorylation in cell metabolism. It is interesting that quite a
few compounds among FDA-approved drugs and the NIH clin-
ical collection also affect cellular metabolism. Further analysis
may help to identify whether the effects of these drugs on meta-
bolism are related to their anti-tumor mechanism and efficacy.
It is also interesting that only a small fraction of compounds
that decrease the NAD+/NADH ratio exhibited obvious cytotox-
icity, whereas the majority of the compounds that increase the
NAD+/NADH ratio exhibited obvious cancer cell toxicity, among
which b-lapachone, shikonin, and fascaplysin were potent,
widely studied anti-tumor agents. Consistent with their effects
on their NAD+/NADH ratio as reported by the SoNar sensor,
b-lapachone is known to be reduced by NQO1, which then en-
ters into futile cycling, consumes NAD(P)H, and generates
superoxide, while shikonin inhibits cancer cell glycolysis by tar-
geting tumor pyruvate kinase M2 (Chen et al., 2011). The other
compounds identified were not previously linked to cellular
metabolism. The most potent compound that increases the
NAD+/NADH ratio and the most potent selective cancer-killing
compound, KP372-1, was previously reported to exert inhibitory
effects on PDK1/Akt signaling pathways, suppressing cell prolif-
eration and inducing/sensitizing cells to apoptosis (Koul et al.,
2006; Mandal et al., 2005, 2006; Zeng et al., 2006). Intriguingly,
we found that the compound actually enhanced Akt phosphory-
lation, contradictory to previous reports, and that various spe-
cific Akt inhibitors had no significant impact on the NAD+/
NADH redox level. KP372-1 induced significant oxidative stress
as shown by NAD(P)H depletion, H2O2 generation, and thiol
oxidation. The PPPwas activated to replenish NADPH for antiox-
idant enzyme catalysis. Further genetic and chemical screening
showed that KP372-1 was reduced by NQO1 in the presence of
NAD(P)H, which enters into a futile redox cycle and generates
superoxide; its anti-tumor activity was blocked by a specific
NQO1 inhibitor or in isogenic NQO1 knockout cells. These data
show that KP372-1’s action on NAD+/NADH redox, oxidative
stress, and viability of cancer cells was due to NQO1-mediated
futile redox cycling, and not the inhibition of Akt signaling. Kinase
inhibitors have been very popular for dissecting signal transduc-
tion pathways and drug discovery. Although investigators are
aware that inhibition of an off-target kinase may contribute to
the observed biological effects of these inhibitors, the results re-
ported here provide an interesting example that a distinct redox
enzyme and mechanism are responsible for the selective cancer
cell-killing effects of a well-known kinase inhibitor, rather than
kinase inhibition itself. NQO1 was highly expressed in numerous
cancer cells (Bey et al., 2007; Cullen et al., 2003; Pink et al.,
2000). b-lapachone, an anti-tumor agent containing the quinone
pharmacophore, can kill cancer cells overexpressing NQO1
regardless of cell cycle phase or p53 status. The quinone phar-
macophore is particularly common in anti-tumor drugs, such
as mitomycin C, b-lapachone, and 17-N-allylamino-17-deme-
thoxygeldanamycin 17-AAG (Siegel et al., 2012). Unlike these
compounds, KP372-1 does not contain a quinone pharmaco-
phore. In view of the NQO1-catalyzed redox cycling of b-lapa-
chone (Pink et al., 2000; Reinicke et al., 2005), we speculate
the possible reaction mechanism of KP372-1, NAD(P)H, and
NQO1 as follows (Figure 6S): KP372-1 contains a quinone mimic
and can be reduced to the ‘‘hydro’’ form by NAD(P)H via a
2-electron reduction catalyzed by NQO1. The hydro form is pre-
sumably unstable and spontaneously auto-oxidizes to its original
parent form, probably through an intermediate (KP372-1(H).-),
which consumes oxygen and generates superoxide. This redox
cycling causes rapid and profound oxidation of NAD(P)H.
Most current NQO1 substrates developed for cancer therapy
have problems in pharmacokinetics, tolerability, delivery, and
bioavailability. For example, b-lapachone suffers from poor
aqueous solubility and a short half-life in vivo (20 min), which
necessitates the use hydroxypropyl-b-cyclodextrin (HPbCD) as
a solubility aid at the doses poorly tolerated (Bair, 2012; Blanco
et al., 2010; Huang et al., 2012). We reasoned that KP372-1
could be a better candidate in future NQO1-dependent chemo-
therapies, as it is one magnitude more potent than b-lapachone;
is capable of being administered orally; has a long half-life, large
volume of distribution, and excellent bioavailability; and is very
well tolerated by mice at the doses required to detect a signifi-
cant anticancer effect. By in vivo imaging of tumor metabolism
using the SoNar sensor, we also demonstrated that KP372-1
enters the tumor rapidly. Furthermore, identification of a non-
quinone redox cycling agent like KP372-1 expands our scope
and understanding of NQO1 and redox cycling agents. These
compounds and their analogs can be further modified and inves-
tigated to develop better anti-tumor drugs.
In summary, we report that SoNar is a superior tool for tracking
the intracellular NAD+/NADH redox state and, therefore, subtle
changes in cell metabolic status, as it is intensely fluorescent,
is intrinsically ratiometric, and has a large dynamic range. These
properties make it an ideal reagent for metabolic studies and
drug discovery in cells or animals. Interestingly, we identified a
potent NQO1-activated redox cycling and anti-tumor agent,
KP372-1, which was previously used as (believed to be) an AktCinhibitor. Further studies on KP372-1 and its analogs might
lead to therapeutic options for drug-resistant cancers. With the
help of the SoNar sensor, we also identified many other com-
pounds, including clinically used drugs that affect cellular
metabolism. Although not investigated in this study owing to
practical considerations of time, effort, and compound availabil-
ity, it is possible that the clinical benefits of these drugs are less
attributable to their reported targets or mechanism of action
and, perhaps, more likely a consequence of effects on cellular
metabolism.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Experimental Procedures for additional details.
All procedures involving animals were approved by the Institutional Animal
Care and Use Committee of Shanghai.
Gene Construction and Protein Characterization
Gene construction and characterization of SoNar in vitro are described in
Supplemental Experimental Procedures.
Live Cell Fluorescence Measurement Using Microplate Reader
Cells were harvested by trypsinization and counted by hemocytometer. Cells
were washed and suspended in PBS (HyClone), and aliquots of cells were
incubated at 37C with different compounds during the measurement. Dual-
excitation ratios were obtained by a Synergy 2 Multi-Mode Microplate Reader
(BioTek). Detailed procedures can be found in the Supplemental Experimental
Procedures.
Fluorescence Microscopy
For fluorescence microscopy, H1299-SoNar-, H1299-cpYFP-, H1299-Hyper-,
and H1299-roGFP1-expressing cells were plated on a 35-mm glass-bottom
dish with phenol red-free growth medium. Images were acquired using a
high-performance fluorescent microscopy system equipped with Nikon
Eclipse Ti-E automatic microscope, monochrome cooled digital camera
head DS-Qi1 Mc-U2, and the highly stable Sutter Lambda XL light source.
Raw data were exported to ImageJ software as 12-bit TIF for analysis. Detailed
procedures can be found in the Supplemental Experimental Procedures.
Imaging NADH Metabolism in Living Animals
H1299-SoNar- and H1299-cpYFP-expressing cells (10 3 106) suspended in
0.1 ml serum-free RPMI1640 with an equal volume of BD Matrigel Matrix
(BD Biosciences, 356237) were inoculated s.c. in the right axilla of each
mouse. When tumor size reached 0.6–1.2 cm in diameter, mice were anesthe-
tized intraperitoneally with sodium pentobarbital (100 mg/kg body weight),
placed in a holding chamber, and given an intravenous tail vein injection
with 100mMsodium pyruvate (Invitrogen) or 600 mMKP372-1 (Echelon Biosci-
ences) suspended in 0.9%NaCl in a total volume of 0.3 ml. The dual-excitation
ratio imaging in tumor tissues expressing SoNar or cpYFP was obtained by a
Kodak Multispectral FX imaging system (Carestream Molecular Imaging) with
excitation filters 420 BP 20 nm and 490 BP 20 nm, and an emission filter 535
BP 50 nm (for both excitation wavelengths).
Chemical Screen and Analysis
All screened compounds were purchased from the National Compounds
Resource Center (China) as stock solutions in DMSO. The majority of the com-
pounds were arrayed in 96-well plates and diluted to 3 mM or 30 mM with PBS
containing 25 mM glucose. We then transferred 25-ml chemical solutions from
96-well plates into black 384-well flat-bottom plates (Greiner Bio-One,
Germany) using an eight-channel pipette and then immediately added 50 ml
H1299-SoNar-expressing cell suspensions into each well using an eight-chan-
nel electronic pipette (50–1,250 ml), resulting in 1-mM and 10-mM final concen-
trations for most compounds. Each plate contained the following control wells:
four to eight wells DMSO-only control, two to four wells controls with 1 mM
pyruvate, and two to four wells controls with 5 mM oxamate. Fluorescence
intensity was measured immediately by a Synergy 2 Multi-Mode Microplateell Metabolism 21, 777–789, May 5, 2015 ª2015 Elsevier Inc. 787
Reader (BioTek) with 420-nm or 485-nm excitation and 528-nm emission
wavelengths. Analysis of screening data is described in Supplemental Exper-
imental Procedures. The I value for every compound performed in our screen
can be found in Table S2.
Metabolomics Analysis
The metabolomic analysis was performed by Metabolon (Durham). Detailed
procedures can be found in the Supplemental Experimental Procedures.
Xenograft Studies
To test the anti-tumor activity of KP372-1 in vivo, nude mice (nu/nu, male 6- to
8-week-old, Shanghai SLAC Laboratory Animal Co.) were injected s.c. with
5 3 106 cells. Animals were divided randomly into control (vehicle),
10 mg/kg prevention, or 20 mg/kg prevention groups of eight each. Treatment
was performed once daily by intragastric administration of KP372-1. Tumor
formation was assessed every 2–3 days with calipers in all the groups. After
4–6 weeks, the tumors were dissected and weighed.
Statistical Analysis
Data are presented either as a representative example of a single experi-
ment repeated at least in triplicate or as three or more experiments. Data
obtained are represented as mean values ± SD or mean values ± SEM. All
p values were obtained using unpaired two-tailed Student’s t test. Values of
p < 0.05 were considered statistically significant (*p < 0.05, **p < 0.01, and
***p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2015.04.009.
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